口腔的扁平苔蘚除了造成疼痛,長期下來也有癌變的危險。扁平苔蘚不容易治療,常常需要另加上口服藥才能控制。很多位於頭皮、指甲的扁平苔蘚如果沒有及時治療,甚至可能造成不可逆的毛髮與指甲脫失。
Chapter 32 :: Lichen Planus Part 2
:: Aaron R. Mangold & Mark R. Pittelkow
鄭煜彬(20200329)
MALIGNANT TRANSFORMATION |
|
How about the risk of malignant
transformation in oral LP? |
Low risk (0.6-1.9%) |
What are the risk factors of malignant
transformation in oral LP? |
Long-standing dz, erosive or atrophic
types, tobacco use, esophageal involvement, oncogenic subtypes of HPV (type
16) |
What is the stage of malignant
transformation in oral LP? |
In situ carcinoma or with a microinvasive
pattern. |
Where is the common sites of malignant
transformation in oral LP? |
Tongue> buccal
mucosa>gingiva>>>lip |
What are the features of malignant
transformation in oral LP? |
Invasive SCC: 1.
Indurated, nonhealing ulcers 2.
Exophytic lesions with a
keratotic surface. 3.
Red atrophic plaques(correlate
with SCC in situ) |
What are the risk factors of SCC in LP ? |
1.
Hypertrophic or verrucous LP 2.
LP on the lower extremity 3.
A history of arsenic exposure 4.
A history of x-ray exposure 5.
Long-standing disease
(average, 12 ys) |
DIAGNOSIS |
|
What should you do for the vesiculobullous
disease or erosive disease of LP? |
Histopathology, DIF, IIF, & ELISA (to
differentiate from immunobullous dzs) Laboratory testing is not required |
What laboratory testing should be
performed in LP? |
Tests for dyslipidemia |
What laboratory testing should be
performed in oral LP? |
Patch tests of mercury, gold, chromate,
flavoring agents, acrylate, & thimerosal |
What laboratory testing should be
performed in LLP? |
Testing for thyroid abnormalities: TSH,
antithyroid peroxidase antibodies, & anti-thyroglobulin antibodies. |
When should you check HCV in the case of
LP? |
Oral LP, risk factors for HCV (↑liver function, IV
drug use, blood transfusion prior to 1992, & high risk sex), in
endemic areas (East and Southeast Asia,
South America, the Middle East, & Southern Europe)臺灣是流行區 |
PATHOLOGY |
|
What are the major pathologic findings of
LP? |
Epidermis: hyperkeratosis, wedge-shaped
areas of hypergranulosis, & elongation of rete ridges (sawtooth) l Basal epidermal keratinocyte damage (effacement of DEJ) l A lichenoid-interface lymphocytic reaction: a dense, continuous,
& band-like lymphohistiocytic infiltrate at the DEJ |
What are the 2 absent features in LP? |
Parakeratosis & eosinophils |
What is the apoptotic cells at the papillary
dermis of LP ? |
Colloid-hyaline bodies=Civatte bodies=
eosinophilic bodies. |
What is the difference between lichenoid
drug eruptions & classic LP? |
Eosinophils (in 2/3 lichenoid drug
eruption) |
What is the difference between hypertrophic
LP & classic LP? |
Eosinophils (in 1/5 hypertrophic LP, thus
they are very itchy.) |
What is Max Joseph cleft formation in LP?
|
Separation of the epidermis in small
clefts under severe inflammation of LP. |
What are the features of late disease of
LP? |
Scarring (an atrophic epidermis,
effacement of the rete ridges, dermal fibrosis), colloid bodies & melanophages. |
What is difference between late disease
of LP & poikiloderma? |
LP: colloid
bodies (+) |
What are the features of hypertrophic LP? |
Hyperkeratosis, acanthosis,
papillomatosis, thick-ened collagen bundles in the dermis, & Eφ. |
What are the differences between mucosal/genital
LP & cutaneous LP? |
Parakeratosis & an absent granular
layer, plasma cells. |
What are the features of LPP? |
A perifollicular, lymphohistiocytic
inflammation at only isthmus & infundibulum + scarring alopecia
(perifollicular fibrosis, scarring, & follicular atrophy) |
What is the features of DIF in LP? |
1.
IgM(±IgG, IgA) on the
apoptotic cells(colloid bodies) at the DEJ 2.
Shaggy deposition of
fibrinogen at the DEJ 3.
Multiple Ig conjugates(IgM,
IgG, IgA): consider LE |
What is the role of DIF in LP? |
1.
More important in oral LP 2.
Atypical disease 3.
Ulcerative and
vesiculobullous LP |
Where is the optimal location for biopsy
of cutaneous LP? |
1.
Proximal trunk 2.
Avoidance of the distal
extremities. |
How do you select optimal location for
biopsy of LPP & nail LP? |
With dermoscopy. |
Where is the proper location of biopsy of
nail LP? |
Surficial change (trachyonychia &
pitting): matrix Change of plate(chromonychia, nail plate
fragmentation), subungual change(splinter hemorrhage, onycholysis, &
subungual debris): nail bed. |
Where are the proper locations of DIF of
LP ? |
1.
Mouth floor & ventral
tongue 2.
Can be 1 cm from the lesion |
DIFFERENTIAL DIAGNOSIS |
|
|
|
|
|
CLINICAL COURSE AND PROGNOSIS |
|
How long is the duration of most
cutaneous LP? |
Resolves within 1-2 years |
How much is the recurrence rate of LP? |
20%, common in generalized cutaneous
disease. |
What is the relationship between duration
& the extent/sites of LP? |
Short to Long: generalized cutaneous <
nongeneralized cutaneous < cutaneous & mucosal < mucosal <
hypertrophic <LPP |
What is the most common manifestation of
LP sequelae? |
Postinflammatory hypo-/hyperpigmentation
(in higher Fitzpatrick skin types) |
TREATMENT(challenging & discouraging) |
|
How can you decrease the severity of LP? |
Discontinue exacerbating drugs, minimize
trauma, & reduce microbial overgrowth |
What is most specific tx of lichenoid
dzs? |
Janus kinase (JAK) inhibitors (target
CD8-Tc cells, also works in DM, AA, & vitiligo) |
CUTANEOUS LICHEN PLANUS |
|
What are the choices of skin-directed Tx
of cutaneous LP? |
Topical: steroids(±occlusion), calcipotriene,
calcineurin inhibitors (esp. combination of steroids) IL: steroids (5-10 mg/mL monthly ± topical steroids) Phototherapy: NBUVB, BBUVB, UVA, PUVA |
What are the special applications of
hypertrophic LP? |
Occlusion of topical steroids, IL
steroids. |
What are the systemic Tx of LP? |
1st: oral steroids 2nd: sulfasalazine, metronidazole, acitretin, hydroxychloroquine/
chloroquine, methotrexate, mycophenolate mofetil (MMF), & azathioprine 3rd: cyclosporine |
How do you choose the systemic Tx of LP ? |
Refractory/ulcerative: target lymphocutes
(methotrexate, MMF, and azathioprine) Generalized/hypertrophic: indirectly on
lymphocytes (sulfasalazine & metronidazole) or cellular differentiation (acitretin) |
How much is the dose of systemic prednisolone
for cutaneous LP? |
0.3-1 mg/kg/ day for 4-6 wks. |
Why is corticosteroid-sparing agents very
important for cutaneous LP therapies? |
Relapse is common after DC steroid |
What drug in 2nd line
therapies has highest efficacy for cutaneous LP? |
Sulfasalazine (1-2.5 g/day) |
What is adverse effects of sulfasalazine?
|
Agranulocytosis & ↑liver function |
What is the role of metronidazole in the Tx
of cutaneous LP? |
1.
The first-line
nonimmunosuppressive systemic agent (250mg tid or 500mg bid) 2.
Effective in generalized
cutaneous LP. |
What is adverse effects of metronidazole? |
Sensory peripheral neuropathy |
What is the role of acitretin in the
therapies of cutaneous LP ? |
Highly effective for hypertrophic LP (30
mg/day) |
What is adverse effects of acitretin? |
Mucocutaneous side effects(xerosis,
scaling) and hyperlipidemia |
What is the role of antimalarials in the Tx
of cutaneous LP ? |
Chloroquine: cutaneous LP. Hydroxychloroquine: LPP, & actinic
LP, favorable side effects |
What is the role of methotrexate in the Tx
of cutaneous LP ? |
Works for recalcitrant disease,
hypertrophic LP, & LPP |
What is drawbacks of MMF, azathioprine,
& cyclosporine? |
MMF: expensive, delayed response (needs
steroids) Azathioprine: suppressive effects on T +
B lymphocytes & poor tolerability Cyclosporine: expensive, frequent
relapses, long-term side effects (kidney insufficiency & lymphoma) |
ORAL LICHEN PLANUS |
|
What is the cornerstone of Tx in oral LP? |
Good oral hygiene with regular
professional dental cleanings |
How can patients minimize exacerbating
factors of oral LP? |
Avoiding contact allergens(removal of
amalgams, gold), DC drug, reducing oral microbes & trauma |
What are the skin-directed Tx of oral LP?
|
1st: topical sterods in
orabase.(Stronger agents: clobetasol & fluocinonide + more occlusive
preparations + 2-6 times daily) 2nd: topical tacrolimus/
pimecrolimus 3rd: topical cyclosporine/tretinoin |
What is the major complication of topical
steroids? |
Fungal infection |
How can you manage the major complication
topical steroids? |
Oral chlorohexidine gluconate mouthwash,
topical anticandidal medications, oral fluconazole |
What is the side effect of topical
calcineurin inhibitors for oral LP? |
Transient burning (improved by combination
of topical steroids) |
What is the role of IL steroid in the Tx
of oral LP? |
Last line (after exhausting topical
therapies, 10-40mg/ml, Q 1-4 wks) |
What are the systemic Tx of oral LP? |
1st: oral steroids 2nd: acitretin,
hydroxychloroquine/ chloroquine, methotrexate, MMF 3rd: cyclosporine, azathioprine… |
How much is the dose of systemic prednisolone
for oral LP? |
1.5-2 mg/kg/ day for 4-6 wks. |
What are the concerns of systemic Tx in
oral LP? (2) |
1.
iatrogenic candida infections 2.
↑risk of oral SCC under erosive & refractory LP &
immunosuppression |
What drugs are preferred in oral LP? (4) |
Erosive LP 1.
MMF 2.
Hydroxychloroquine (less
immunosuppressive) 3.
Methotrexate (less immunosuppressive) Hyperkeratotic/noneroded LP 4.
Acitretin (antiploliferative,
less immunosuppressive) |
How much is the dose of systemic steroids
for oral LP? |
Prednisolone: 1.5-2 mg/kg (higher than
skin, more side effects) Betamethasone: 5 mg on 2 consecutive days
weekly (pulse tx: less side effects) |
What oral drugs can be considered in oral
LP? |
1.
Acitretin 30mg/day 2.
Alitretinoin 30mg/day (臺灣沒有) |
What are first choices of steroid-sparing
agents for oral LP? (2) |
1.
Methotrexate (10-15mg/wk) 2.
MMF (2-3g/day) |
Tx of LPP |
|
Why does LPP & FFA cause scarring
alopecia? |
Deficiency of PPARγ→loss of immune privilege→destruction of the
bulge |
What are the skin-directed Tx of LPP? |
1st: mid to high potency steroids(topical
or IL) 2nd: calcineurin inhibitors |
What are the systemic Tx of LPP? |
1st: prednisolone 1 mg/kg/day 2nd: Hydroxychloroquine (+
doxycycline, not monotherapy),
MMF, methotrexate 3rd: cyclosporine (monotherapy) |
Tx of FFA |
|
What are the skin-directed Tx of FFA? |
IL steroid, topical minoxidil (combine hydroxychloroquine
or others) |
What are the systemic Tx of FFA? |
1.
5 α-reductase inhibitors (finasteride
2-5mg/day or dutasteride 0.5mg every 1-7 days) 2.
Systemic steroids + MTX &
MMF 3.
Cyclosporine (monotherapy) |
NAIL LICHEN PLANUS |
|
What is the goal of the therapy of nail
LP? |
Stop the disease (prevent irreversible
pterygium), not reverse it. |
What is the therapies of nail LP? |
Ultrapotent topical & intralesional
steroids→syetemic steroids (for compromise of function & debilitating
pain) or hydroxychloroquine |
I am very grateful to your for providing this information.because mostly people have been a victimize of this problem.
ReplyDeletethanks for sharing this.
Regards,
Lichen planus pigmentosus specialist